AFM
IMPL

Anson Funds Management’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Anson Funds Management’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,729
Closed -$153K – 453
2021
Q4 		$153K Buy
+17,729
New +$177K 0.02% 317

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Anson Funds Management's IMPL Position: Q1 2022 in Review

Anson Funds Management sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q1 2022, closing a stake of 17,729 shares — an estimated $153K sold.

Anson Funds Management first reported a position in IMPL in Q4 2021 and held it in 1 quarter. The position peaked at $153K in Q4 2021. 42 funds tracked by Wall St. Rank hold IMPL as of Q1 2022.

  • Anson Funds Management reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 17,729 Impel Pharmaceuticals Inc. Common Stock shares in Q1 2022, an estimated $153K.
  • Anson Funds Management first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's Impel Pharmaceuticals Inc. Common Stock position peaked at $153K in Q4 2021.
  • 42 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.